Theratechnologies Inc T.TH

Alternate Symbol(s): THTX

Healthcare Biotechnology

Theratechnologies Inc. is a Canada-based clinical-stage biopharmaceutical company. The Company is focused on the development and commercialization of therapies addressing unmet medical needs. It markets prescription products for people with human immunodeficiency viruses (HIV) in the United States. The Company's research pipeline focuses on specialized therapies addressing unmet medical needs in HIV, nonalcoholic steatohepatitis (NASH) and oncology. Its medicines include Trogarzo and EGRIFTA SV (tesamorelin for injection). Trogarzo (ibalizumab-uiyk) injection is a long-acting monoclonal antibody which binds to domain 2 of the CD4 T cell receptors. It blocks viral entry into host cells while preserving normal immunologic function. The Company is also investigating an intramuscular method of administration of Trogarzo. EGRIFTA SV (tesamorelin for injection) is approved in the United States for the reduction of excess abdominal fat in people with HIV who have lipodystrophy.

TSX:TH - Post by User

Theratechnologies Inc

Bullboard Posts

Comment by 1998novlon Jul 24, 2020 8:53am

177 Views

Post# 31312996

RE:Gene Expression - HIV NASH

I get the sense here that Tesamoralin is the newest game changer. Old Dog, new trick - liver saving. This gene data leads me to believe they will have no issue getting approval in Europe now, with protection. Now I understand why General NASH was always on the table. Shout out to Luc today for his patience. Hope he breaks 75 today on the course.

Bullboard Posts

98% energy efficiency: How Acceleware's EM Technology is transforming heat solutions